Eleanor Stuart

Life Science Researcher at Airfinity Ltd

Eleanor Stuart has worked as a Life Science Researcher at Airfinity Ltd since August 2021. Prior to that, they conducted a fourth-year research project at the University of Cambridge from October 2020 to March 2021. In this role, they focused on researching the effect of the anti-viral drug vidarabine on DNA replication using budding yeast as a model organism. Eleanor gained experience in various techniques such as cloning, mutagenesis, PCR, flow cytometry, and western blotting. Eleanor also utilized Unix and R for data analysis of DNA sequencing data.

Before their fourth-year project, Eleanor was involved in a third-year research project at the University of Cambridge from January 2020 to March 2020. During this project, they investigated the impact of ApoE isoforms on microglial phagocytosis and TREM2 activation in the context of Alzheimer's Disease. Eleanor gained experience with techniques such as cell culture, flow cytometry, reporter cell lines, and immunofluorescence. Eleanor also had the opportunity to write up their research and discuss its implications within the field.

Additionally, Eleanor was a Summer Intern at the University of Oxford from July 2019 to September 2019. Their work focused on the effect of gestational diabetes on embryonic heart development. In this role, they utilized techniques like histology, immunohistochemistry, and 3D modeling of hearts using Amira.

Eleanor Stuart attended the University of Cambridge from 2017 to 2021, where they pursued a degree in Natural Sciences. Their field of study was specifically focused on Biochemistry.

Location

London, United Kingdom

Links

Previous companies


Org chart

This person is not in the org chart


Teams


Offices


Airfinity Ltd

Airfinity is a pioneer in predictive health analytics that decision makers can trust, understand and act on to preempt future health risks.Specialising in infectious diseases, Airfinity has a comprehensive suite of world-leading market intelligence solutions, turning disconnected data points into real time predictive indicators. The platform alsocovers advanced therapies (e.g. RNA, Gene and Cell Therapy) and cardio-metabolic.Disease-centric solutions combine proprietary surveillance tools and forecast models with expert analysis to produce actionable insights on pipeline developments, standard of care, regulatory trends and demand and supply.Airfinity is a global company with headquarters in London and Boston, relied upon across the full ecosystem in life sciences, including pharma companies, government agencies, corporates, investors, NGOs, and international organisations.


Employees

51-200

Links